Qilu Children's Hospital of Shandong University
9
2
2
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
22%
2 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Chinese PICU Collaborative Network on Pathogens and Drug Resistance of Severe Infections
Role: collaborator
Epidemiological Study for Bronchopulmonary Dysplasia (BPD) in China
Role: collaborator
Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases
Role: collaborator
Acute Sympotomatic Seizure Secondary to Autoimmune Encephalitis and Autoimmune-associated Epilepsy
Role: collaborator
PIVKA-II Combined With Alpha-Fetoprotein for Diagnostic and Prognostic Value of Hepatic Tumors in Infants
Role: collaborator
Clinical Study of Reduning Injection for the Treatment of Influenza in Children
Role: collaborator
Multicenter Registry of Pediatric Lupus Nephritis in China
Role: collaborator
Effect of Recombinant Human Interferon α-2b Spray on Herpangina
Role: collaborator
A Registry Study of 100 Thousand Cases of Pediatric Patients on Reduning Injection（a Chinese Medicine Injection）Used in Hospitals in China
Role: collaborator
All 9 trials loaded